Manish Sagar (0000-0001-9803-6594)

Personal information

Biography

Dr. Manish Sagar is an Associate Professor of Medicine at the Boston University School of Medicine. He was recruited to the Boston University Medical Campus from Brigham and Women’s Hospital in 2012. Dr. Sagar’s research focuses on the pathogenesis of human immunodeficiency virus type 1 heterosexual transmission. He has been a member of the AIDS Clinical Trials Group (ACTG) since 2005. Dr. Sagar has served on numerous committees including NIH study sections and Doris Duke Charitable Foundation Early Career Development Award Review Committee. He is an active member of the Infectious Diseases Society of America (IDSA).

Activities

Collapse all

Genomic Epidemiology of Respiratory Syncytial Virus in a New England Hospital System, 2024

2025-02-23 | Preprint

DOI: 10.1101/2025.02.21.25322621

Contributors: Emily LaVerriere; Sasha Behar; Cole Sher-Jan; Yan Mei Liang; Manish Sagar; John H. Connor

Manish Sagar

https://orcid.org/0000-0001-9803-6594

Personal information

Emails & domains

Verified email addresses

Verified email domains

Websites & social links

Biography

Activities

Works (36)

Genomic Epidemiology of Respiratory Syncytial Virus in a New England Hospital System, 2024

Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence

Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Associates With Unstable Housing and Occurs in the Presence of Antibodies

Antibody-dependent cellular cytotoxicity responses and susceptibility influence HIV-1 mother-to-child transmission

Family matters for coronavirus disease and vaccines

Pre-existing infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity

Coronavirus Disease 2019 Mitigation Strategies Were Associated With Decreases in Other Respiratory Virus Infections

Distinct Autoimmune Antibody Signatures Between Hospitalized Acute COVID-19 Patients, SARS-CoV-2 Convalescent Individuals, and Unexposed Pre-Pandemic Controls

Recent endemic coronavirus infection is associated with less-severe COVID-19

HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility

HIV-1 co-receptor usage and variable loop contact impacts V3 loop bnAb susceptibility

HIV-1 replicates and persists in vaginal epithelial dendritic cells

Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity

Long-Term Reduction in Peripheral Blood HIV-1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.

Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions.

Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C.

Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.

Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.

Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.

HIV-1 transmission biology: selection and characteristics of infecting viruses.

Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.

Selection of HIV variants with signature genotypic characteristics during heterosexual transmission.

In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.

Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.

Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection.

No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate.

Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.

Effect of contraceptive methods on natural history of HIV: studies from the Mombasa cohort.

Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes.

Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population.

Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression.

Transmission of Histoplasma capsulatum by organ transplantation.

p53 and tumor necrosis factor alpha regulate the expression of a mitochondrial chloride channel protein.

Cooperation of p53 loss of function and v-Ha-ras in transformation of mouse keratinocyte cell lines.

Refining the treatment of women with unstable angina--a randomized, double-blind, comparative safety and efficacy evaluation of Integrelin versus aspirin in the management of unstable angina.

Peer review (34 reviews for 14 publications/grants)